Insider Trading March 4, 2026 03:43 AM

Par Pacific SVP Disposes $638K in Shares as Stock Trades Near Yearly Peak

Senior vice president Jeffrey Ryan Hollis sold 15,350 shares while the company reports mixed fourth-quarter results and receives an analyst upgrade

By Leila Farooq PARR
Par Pacific SVP Disposes $638K in Shares as Stock Trades Near Yearly Peak
PARR

Jeffrey Ryan Hollis, Par Pacific Holdings' Senior VP - General Counsel and Secretary, sold 15,350 shares on February 27, 2026, for roughly $638,867 at prices between $41.62 and $41.67. The insider now holds 19,769 shares. The sale comes as PARR shares trade close to a 52-week high of $48.40 following a 267% gain over the past year. Par Pacific’s Q4 2025 results showed an EPS of $1.17 versus a $1.62 forecast and revenue of $1.81 billion versus $1.69 billion expected. InvestingPro flags PARR as undervalued with a P/E of 6.36, and Raymond James reiterated an Outperform rating with a $50 price target.

Key Points

  • Senior VP Jeffrey Ryan Hollis sold 15,350 Par Pacific (PARR) shares on Feb. 27, 2026, for approximately $638,867 at prices between $41.62 and $41.67.
  • After the sale Hollis directly owns 19,769 shares; the stock is trading near a 52-week high of $48.40 following a 267% return over the past year.
  • Par Pacific reported Q4 2025 EPS of $1.17 versus a $1.62 forecast (27.78% miss) and revenue of $1.81 billion versus $1.69 billion expected (7.1% surprise); Raymond James reiterated an Outperform rating with a $50 price target.

Insider transaction details

Jeffrey Ryan Hollis, who serves as Senior Vice President - General Counsel and Secretary at Par Pacific Holdings (NYSE:PARR), sold 15,350 shares of the company's common stock on February 27, 2026. The transaction generated approximately $638,867, with sale prices recorded in a narrow band from $41.62 to $41.67. Following this disposition, Hollis is listed as directly owning 19,769 shares of Par Pacific Holdings.


Market context and valuation notes

The insider sale occurred while the stock is trading near a 52-week high of $48.40, after a reported year-to-date return of 267% over the prior 12 months. Analysis cited from InvestingPro in the company filing indicates that PARR appears on that platform’s list of most undervalued stocks and is trading at a price-to-earnings ratio of 6.36. The InvestingPro note additionally references 11 supplementary tips available through the platform for deeper analysis.


Earnings and analyst coverage

Par Pacific disclosed its fourth-quarter 2025 earnings, reporting earnings per share of $1.17, which fell short of the consensus forecast of $1.62 - a shortfall quantified at 27.78%. Revenue for the quarter came in at $1.81 billion, exceeding the anticipated $1.69 billion and representing a 7.1% upside to expectations.

In the wake of the results, Raymond James maintained an Outperform rating on Par Pacific and kept a $50.00 price target. The firm noted potential for considerable upside tied to the company’s focus on refining improvements, growth initiatives, and balance-sheet optimization.


Implications for investors

The combination of an insider sale, strong revenue performance, an EPS miss, third-party valuation commentary, and continued positive analyst coverage presents a mixed set of datapoints for shareholders and market participants to weigh as they assess Par Pacific’s near-term prospects.

Risks

  • Earnings per share in Q4 2025 missed consensus estimates by 27.78%, a near-term performance risk that may influence investor sentiment - impacts equity investors and shareholders.
  • The insider sale occurred while the stock trades near a 52-week high, which may raise questions among market participants about timing and insider confidence - impacts market perception and trading activity.
  • Valuation signals are mixed: InvestingPro lists PARR as undervalued with a P/E of 6.36, while the stock has already logged strong price appreciation, creating uncertainty about near-term upside - impacts equity valuation assessments.

More from Insider Trading

Enliven Therapeutics CMO Sells 4,900 Shares in Rule 10b5-1 Transaction Apr 21, 2026 Sionna Therapeutics Director Disposes of $2.47M in Stock Under 10b5-1 Plan Apr 21, 2026 OrbiMed Entities Dispose of $2.47M in Sionna Therapeutics Shares Apr 21, 2026 Planet 13 Operations VP Disposes of 32,500 Shares Worth $4,904 Apr 21, 2026 FreeCast CEO-Controlled Entity Sells $3.3M in Class A Shares as Convertible Notes Are Converted and Renewed Apr 21, 2026